Clinical Question: Is there any significant difference in bleeding risk between apixaban and rivaroxaban when used to treat acute venous thromboembolism (VTE)?
Background: Acute VTE is a highly prevalent condition. Nearly all patients with new VTE will require a minimum of 90 days of anticoagulation. There have been no previous trials that compare apixaban and rivaroxaban head-to-head concerning bleeding risk when used to treat acute VTE.
Study Design: International, prospective, randomized, open-label, blind endpoint study
Setting: 32 medical centers in Canada, Australia, and Ireland
Synopsis: 2,760 patients 18 years or older with symptomatic acute VTE were randomized to receive either apixaban or rivaroxaban for three months. Over the course of the three-month trial period, 44 of 1,345 patients (3.3%) in the apixaban arm and 96 of 1,355 patients (7.1%) in the rivaroxaban arm experienced the primary outcome of clinically relevant bleeding, represented by a composite of major bleeding or clinically significant nonmajor bleeding as defined by the International Society on Thrombosis and Haemostasis. There were no significant differences in non-bleeding-related adverse events between the apixaban arm (2.7%) and the rivaroxaban arm (2.2%). Limitations include the possibility of ascertainment bias given the open-label nature of the study, and the lack of data regarding bleeding beyond the initial 90-day treatment period for those requiring longer treatment durations. Outcomes from this study cannot be applied to patients with other indications for direct oral anticoagulant use. A similar trial for patients with atrial fibrillation is ongoing at the time of publication.
Bottom Line: For patients with acute VTE, apixaban is associated with decreased risk of clinically relevant bleeding in the first 90 days of treatment.
Citation: Castellucci LA, et al. Bleeding risk with apixaban vs. rivaroxaban in acute venous thromboembolism. N Engl J Med. 2026;394(11):1051-1060. doi:10.1056/NEJMoa2510703.
Dr. Larson
Dr. Larson is a hospitalist in the division of hospital medicine at NYU Langone’s Tisch Hospital and Kimmel Pavilion and medical director for Unit 14 West at Tisch Hospital, all in New York.